Ironwood Pharmaceuticals to Present at the Goldman Sachs 39th Annual Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 6, 2018--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the Goldman Sachs 39 th Annual Global Healthcare Conference on Wednesday, June 13 th, 2018 at 4:00 p.m. Pacific Time (7:00 p.m. Eastern Time) at the Terranea Resort in Rancho Palos Verdes, California.
A live webcast of Ironwood’s presentation will be accessible through the Investors section of the company’s website at www.ironwoodpharma.com. To access the webcast, please log on to the Ironwood website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Ironwood’s website for 14 days following the conference.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals (NASDAQ: IRWD) is a commercial biotechnology company focused on creating medicines that make a difference for patients, building value for our fellow shareholders, and empowering our passionate team. We are commercializing two innovative primary care products: linaclotide, the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC), and lesinurad, which is approved to be taken with a xanthine oxidase inhibitor (XOI), or as a fixed-dose combination with allopurinol, for the treatment of hyperuricemia associated with gout. We are also advancing a pipeline of innovative product candidates in areas of significant unmet need, including persistent gastroesophageal reflux disease, diabetic nephropathy, heart failure with preserved ejection fraction, achalasia and sickle cell disease. Ironwood was founded in 1998 and is headquartered in Cambridge, Mass. For more information, please visit www.ironwoodpharma.com or www.twitter.com/ironwoodpharma; information that may be important to investors will be routinely posted in both these locations.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180606006257/en/
CONTACT: Ironwood Pharmaceuticals, Inc.
Meredith Kaya, 617-374-5082
Vice President, Investor Relations and Corporate Communications
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA MASSACHUSETTS
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL DIABETES
SOURCE: Ironwood Pharmaceuticals, Inc.
Copyright Business Wire 2018.
PUB: 06/06/2018 04:05 PM/DISC: 06/06/2018 05:46 PM